Iovance Biotherapeutics annual operating margin
2023
2024
2025
Iovance Biotherapeutics Operating Margin Growth & History (IOVA)
Iovance Biotherapeutics's operating margin was −153.08% for fiscal 2025.
View full Iovance Biotherapeutics company overviewIovance Biotherapeutics annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −153.08% | +87.85 pp |
| 2024 | 2024-12-31 | −240.92% | +38494.07 pp |
| 2023 | 2023-12-31 | −38,734.99% | — |
Iovance Biotherapeutics quarterly operating margin
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −52.26% | +137.51 pp |
| Q1 2026 | 2026-03-31 | −113.46% | +132.31 pp |
| Q4 2025 | 2025-12-31 | −84.66% | +32.82 pp |
| Q3 2025 | 2025-09-30 | −140.69% | +11.42 pp |
| Q2 2025 | 2025-06-30 | −189.78% | +137.86 pp |
| Q1 2025 | 2025-03-31 | −245.76% | +16218.85 pp |
| Q4 2024 | 2024-12-31 | −117.48% | +25119.41 pp |
| Q3 2024 | 2024-09-30 | −152.11% | +46102.52 pp |
| Q2 2024 | 2024-06-30 | −327.63% | — |
| Q1 2024 | 2024-03-31 | −16,464.62% | — |
| Q3 2023 | 2023-09-30 | −25,236.89% | — |
| Q2 2023 | 2023-06-30 | −46,254.62% | — |
Iovance Biotherapeutics operating margin trends
Across the available reported history, Iovance Biotherapeutics's operating margin increased from −240.92% to −153.08%, a change of +87.85 percentage points. The latest reported quarter, Q2 2026, shows −52.26%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Iovance Biotherapeutics filings at SEC.gov ↗